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Kinase Suppressor of Ras 2 (KSR2) expression in
the brain regulates energy balance and glucose
homeostasis
Lili Guo 1,2,4, Diane L. Costanzo-Garvey 1,2,4, Deandra R. Smith 1,2,4, Beth K. Neilsen 1,2,
Richard G. MacDonald 1,2,3, Robert E. Lewis 1,2,*
ABSTRACT
Objective: Kinase Suppressor of Ras 2 (KSR2) is a molecular scaffold coordinating Raf/MEK/ERK signaling that is expressed at high levels in the
brain. KSR2 disruption in humans and mice causes obesity and insulin resistance. Understanding the anatomical location and mechanism of
KSR2 function should lead to a better understanding of physiological regulation over energy balance.
Methods: Mice bearing floxed alleles of KSR2 (KSR2fl/fl) were crossed with mice expressing the Cre recombinase expressed by the Nestin
promoter (Nes-Cre) to produce Nes-CreKSR2fl/fl mice. Growth, body composition, food consumption, cold tolerance, insulin and free fatty acid
levels, glucose, and AICAR tolerance were measured in gender and age matched KSR2/ mice
Results: Nes-CreKSR2fl/fl mice lack detectable levels of KSR2 in the brain. The growth and onset of obesity of Nes-CreKSR2fl/fl mice parallel
those observed in KSR2/ mice. As in KSR2/ mice, Nes-CreKSR2fl/fl are glucose intolerant with elevated fasting and cold intolerance. Male
Nes-CreKSR2fl/fl mice are hyperphagic, but female Nes-CreKSR2fl/fl mice are not. Unlike KSR2/ mice, Nes-CreKSR2fl/fl mice respond normally
to leptin and AICAR, which may explain why the degree of obesity of adult Nes-CreKSR2fl/fl mice is not as severe as that observed in KSR2/
animals.
Conclusions: These observations suggest that, in the brain, KSR2 regulates energy balance via control of feeding behavior and adaptive
thermogenesis, while a second KSR2-dependent mechanism, functioning through one or more other tissues, modulates sensitivity to leptin and
activators of the energy sensor AMPK.
 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
The brain plays a critical role in sensing energy demands and regu-
lating fuel storage to maintain body weight within a tight range.
Extensive analysis has identified key conserved genes and neural
pathways critical in regulating energy balance [1,2]. At the core of this
homeostatic pathway is the central melanocortin system, which is
composed of the melanocortin 4 receptor (Mc4r), its agonist a-me-
lanocyte-stimulating hormone (a-MSH), which is derived from cleav-
age of the precursor polypeptide proopiomelanocortin (POMC), and the
Mc4r inverse agonist, Agouti gene-related peptide (AgRP). Orexigenic
Neuropeptide Y (NPY) is co-expressed with AgRP. The anorexigenic
peptide leptin feeds back on the melanocortin system, activating POMC
neurons to stimulate the generation and release of á-MSH. Coincident
with this stimulatory action, leptin also limits the inhibitory signals in
this pathway by inhibiting NPY/AgRP neurons and suppressing the
production and release of NPY and AgRP. Genetic manipulation of
these pathways in preclinical models and the identification of mela-
nocortin pathway mutations in humans has led to strategies for
therapeutic intervention that may modulate energy balance in humans
to ameliorate obesity and its associated co-morbidities [3,4]. However,
additional targets that play limited and narrowly defined roles in
affecting energy balance may provide therapeutically tractable targets
with reduced off-target effects.
Kinase Suppressor of Ras 2 (KSR2) is a molecular scaffold coordinating
Raf/MEK/ERK signaling that potently regulates energy consumption
and expenditure [5e7]. Like its paralog Kinase Suppressor of Ras 1
(KSR1) [8e10], KSR2 coordinates the interaction of Raf/MEK/ERK
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signaling to facilitate signal transduction and regulate the intensity and
duration of ERK signaling [6]. KSR2 also promotes activation of the
primary regulator of cellular energy homeostasis, 50-adenosine
monophosphate-activated protein kinase (AMPK) [5,7]. KSR2 was
found to interact directly with AMPK [5], and ectopic expression of
KSR2 enhanced AMPK activation and signaling in a cell autonomous
manner [7]. However, defective AMPK activation was also observed in
the adipose tissue of mice even though KSR2 mRNA is not significantly
expressed there. These observations suggest that KSR2 may have cell
autonomous and cell non-autonomous effects on this key energy
sensor.
KSR2/ mice develop normally but grow slowly immediately after
birth. Increased adiposity is evident after weaning at 8e9 weeks of
age [5]. In the DBA1/LacJ mouse strain, KSR2 disruption causes
hyperactivity without hyperphagia, revealing that increased adiposity
results from a defect in energy expenditure [5]. Disruption of KSR2
in C57BL/6 mice caused obesity and hyperphagia, which led some
to conclude that KSR2-dependent regulation of food consumption
was the sole cause of obesity in KSR2/ mice [11]. Doubt was
cast on this contention by pair-feeding experiments showing that
hyperphagia exacerbates, but does not cause, obesity in C57BL/6
mice KSR2/ mice. KSR2/ mice are also profoundly insulin-
resistant in liver and adipose tissue [12]. Insulin resistance
appears to be secondary to the obesity, as dietary restriction
after weaning prevents obesity and glucose intolerance in KSR2/
mice. Insulin resistance returns when KSR2/ mice are fed ad
libitum [13].
In KSR2/mice, decreased AMPK activation may impair the oxidation
of fatty acids and increase their storage as triglycerides, contributing to
obesity and insulin resistance [5]. Some KSR2 mutations in individuals
with early-onset obesity disrupt ERK activation or impair interaction of
the scaffold with AMPK [12]. These data identify KSR2 as a key effector
in whole-body energy regulation in mice and humans. The recent
identification of KSR2 mutations in humans, in combination with the
observation that humans bearing these mutations have phenotypic
characteristics found in KSR2/ mice [5,11,12] suggests that KSR2
and KSR2-regulated pathways may be potential targets for therapeutic
intervention for type 2 diabetes and obesity.
KSR2 is expressed abundantly in many areas of the brain, but in
relatively low levels in muscle, liver, and adipose tissue [5,14]. Within
the brain, KSR2 expression is highest in the cortex and cerebellum
and somewhat lower in the hippocampus, hypothalamus, amygdala,
substantia nigra, and various areas of basal ganglia [1A]. We recently
reported that growth hormone (GH) signaling is altered in the liver of
KSR2/ mice and that some of the phenotypic changes observed in
these mice, especially decreased body length, can be rescued by
administration of IGF-1 during the neonatal period [15]. Nevertheless,
hepatocytes isolated from KSR2/ mice exhibited normal GH-
induced signaling under in vitro culture conditions. These findings
suggested that the systemic effects of KSR2 knockout might be
mediated in part by a cell non-autonomous mechanism. We hy-
pothesized that the source of this regulation is the brain. Here we
show that brain-specific disruption of KSR2 is sufficient to reduce
body temperature, promote cold intolerance, cause obesity, and
impair glucose homeostasis, while elevating fasting insulin and free
fatty acid levels in blood. Disruption of KSR2 selectively in the brain
causes hyperphagia in male, but not female, mice. Though still
obese, adiposity in female mice lacking KSR2 in the brain is corre-
spondingly reduced. These data demonstrate that KSR2 functions
centrally to regulate energy balance through effects on feeding
behavior and adaptive thermogenesis.
2. MATERIALS AND METHODS
2.1. Animals
KSR2/ mice were generated as previously described [5,13]. Nes-
CreKSR2fl/fl mice were generated by crossing B6.Cg-Tg(Nes-cre)1Kln/
J, (Jackson Labs; hereafter referred to as ‘Nes-Cre’) to mice in which
LoxP sites had been inserted flanking exon 3 of the KSR2 locus (KSR2fl/
fl, inGenius Targeting Laboratory, Ronkonkoma, NY, Figure 1). The
Institutional Animal Care and Use Committee (University of Nebraska
Medical Center, Omaha, NE) approved all studies. Animals were
maintained on a 12-h light/dark schedule and had free access to
laboratory chow (Harlan Teklad LM 485) and water, except as
described below.
2.2. Dual energy X-ray absorptiometry (DEXA)
Mice were weighed weekly on a digital scale. Lean mass and fat mass
were quantified every two weeks by dual-energy X-ray absorptiometry
(DEXA) with a Lunar PIXImus densitometer (GE Medical-Lunar,
Madison, WI). Mice were anesthetized using a mixture of inhaled
isoflurane and oxygen (anesthetization using 3% isoflurane and 1 L/
min oxygen; maintenance using 1e2% isoflurane and 1 L/min oxygen)
and placed prone on the imaging positioning tray. Adipose mass was
determined by excising and weighing each fat depot after euthanasia.
2.3. Glucose tolerance test (GTT) and 5-aminoimidazole-4-
carboxamide-1-b-D-ribofuranoside (AICAR) tolerance test (ATT)
To determine the role KSR2 plays in glucose homeostasis, mice were
assessed by GTT and ATT. Each GTT was performed after a 10-h
overnight fast; each ATT was performed following a 4-h morning
fast. Mice were injected intraperitoneally (IP) with D-glucose (20%
solution, 2 g/kg of body weight) for GTT, or with AICAR (0.25 g/kg of
body weight) for ATT. Glucose levels were determined in blood
collected from the tail vein at the indicated times following injection.
2.4. Metabolite assays
Blood was collected by tail bleeds of live animals or via cardiac
puncture of euthanized animals. Animals were fasted overnight for
10e12 h prior to collection for blood glucose and serum insulin
measurements. Blood glucose was measured with a Bayer Contour
Glucometer. For serum analysis, blood was allowed to clot at 4 C for
8e24 h, and the serum was separated by centrifugation for 10 min at
10,000 rpm. Serum was transferred to a new tube and stored
at 80 C until assayed. Serum insulin was measured with the Ultra
Sensitive Mouse Insulin ELISA Kit (Chrystal Chem, Downers Grove, IL)
using mouse standards. Serum leptin was measured with a Mouse
Leptin ELISA kit (Millipore, Billerica, MA). Serum free fatty acid (FFA)
levels were quantified using a Free Fatty Acids Half Micro Test
(11383175001, Roche, Indianapolis, IN).
2.5. Measurement of food intake
Food intake was calculated by single-housing mice for 4e5 days, and
taking a daily average of grams of food consumed during that time
period. The effect of chronic leptin treatment on food intake was
measured in mice that were allowed to acclimate 2 days prior to
starting the experiment. On subsequent days, mice were given
phosphate-buffered saline (PBS) or leptin (2.5 mg/kg in PBS) intra-
peritoneally, 2 h prior to the onset of the dark cycle, and food intake
was measured over a 24-hour period (dose 1). The above experiment
was repeated twice more (dose 2 and dose 3), allowing for food intake
to normalize between doses. All mice served as their own controls,
receiving PBS first, followed by leptin.
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2.6. Histology
Lipid accumulation in mice was visualized by hematoxylin and eosin
staining of sections of white adipose tissue (WAT) and brown adipose
tissue (BAT). The tissues were fixed overnight in 4% para-
formaldehyde, and transferred to 70% ethanol until paraffin embed-
ding. Sections were 4e6 mm.
2.7. Rectal temperature and cold tolerance study
Five-month-old mice were individually housed and rectal temperatures
were taken using a MicroTherma 2T handheld thermometer (Ther-
moWorks, Lindon, UT) during resting (2 pm) and active (9 pm) time
periods. For the cold tolerance study, six-month-old male mice were
fasted overnight for 10 h. Mice were then housed individually and
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Figure 1: Selective disruption of KSR2 in brain. A: Schematic representation of the WT, KSR2fl/fl, and recombined alleles lacking KSR2 exon 3 (Nes-CreKSR2fl/fl). LoxP and FRT
sites are indicated as open and closed arrowheads, respectively. Solid arrows indicate the relative positions of primers used to determine presence of Neo. Dashed arrows
represent the primers used to detect the 50 LoxP site. The sizes of PCR products generated from WT, KSR2fl/fl, and Nes-CreKSR2fl/fl are 1004 bp, 1184 bp and 428 bp respectively.
PCR using the primers indicated in panel A to determine the presence or absence of exon 3 of KSR2 in WT, KSR2fl/fl, Nes-Cre, or Nes-CreKSR2fl/fl mice. C: Western blot of KSR2 in
lysates of brain from KSR2/, WT, Nes-Cre, KSR2fl/fl, or Nes-CreKSR2fl/fl mice. D: qPCR for KSR2 mRNA in lysates of brain, pituitary, liver, white adipose tissue (WAT), skeletal
muscle (Quad), and kidney from WT, Nes-Cre, KSR2fl/fl, or Nes-CreKSR2fl/fl mice. Ct values for WT samples are shown for comparison of KSR2 mRNA levels between tissues.
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placed for an additional 2.5 h in micro-isolator cages that had been
acclimated to 4 C. Rectal temperatures were monitored at the times
indicated.
2.8. Immunoblots
Fifteen minutes after AICAR injection, mice were sacrificed, and sub-
cutaneous white adipose tissue was removed, frozen in liquid N2, and
stored at 80 C until use. Whole-cell lysates were made with 50e
100 mg of tissue homogenized in 1% NP-40 lysis buffer. Protein was
run on SDS-PAGE gels, using antibodies recognizing phospho-50-
AMPK (phospho AMPK Thr172, Cell Signaling #2531), 50-AMPK sub-
unit alpha (AMPKá, Cell Signaling #2532), phospho acetyl-CoA-
carboxylase (phospho ACC Ser79, Cell Signaling #3661), acetyl-CoA-
carboxylase (ACC, Cell Signaling #3676) and a-tubulin (Santa Cruz,
8017).
2.9. Quantitative PCR
Tissues were removed from mice after sacrifice and immediately
frozen on dry ice or liquid nitrogen and stored at 80 C. RNA was
extracted using TRI Reagent (Molecular Research Center) and RNeasy
kit (Qiagen). After treatment with DNase I (Ambion, AM1906), cDNA
was synthesized using iScript RT Supermix (BioRad) according the
manufacturer’s instructions. Quantitative real-time PCR was per-
formed in a 20-ml reaction volume using SsoAdvanced Sybr Green
Supermix (BioRad). All reactions were performed in duplicate on a
Stratagene MxPro3000p detection system, and relative RNA levels
were calculated by using 18S rRNA as internal control. The data were
processed using an R script based on the qBase relative quantification
framework [16] with the following modifications. The square root of
(h-1) replaces (h1) in Formula 4. The term 1/slope replaces 1/
slope as the exponential component in Formula 5. SD should be SE (a
presumed typographical error) in Formula 12. Primer sequences
were: 18S rRNA: 50-GTAACCCGTTGAACCCCATT-30 and 50- CCATC-
CAATCGGTAGTAGCG-30 KSR2: 50-TGGATGTCCGAAAGGAAGTC-30 and
50-CTTCTCCACGGTCTCACACA-30UCP1: 50- TACCAAGCTGTGCGATGT-
30 and 50- AAGCCCAATGATGTTCAGT-30
2.10. Statistical analysis
GraphPad Prism version 5.04 for Windows (GraphPad Software, San
Diego, CA) was used for graphics design and statistical analyses. To
determine the extent to which disruption of KSR2 affected the indi-
cated response variable at a single time point, a Student’s t-test was
used, applying a Bonferroni adjustment when multiple pairwise
comparisons were made [17]. To determine the effect of KSR2
disruption on the indicated response variable over time or under
various treatments, a two-way analysis of variance (ANOVA) was
applied with genotype as the independent variable and time/age as
the dependent factors [17]. When multiple data points were drawn
sequentially from the same animal, pseudoreplication was avoided by
performing a repeated measures two-way ANOVA. When results from
the two-way ANOVA indicated that genotype had a significant effect,
we performed as appropriate Dunnett’s post-test or an additional
series of Bonferroni-adjusted Student’s t-tests to identify the time
points at which or treatments under which the effect of KSR2
disruption became significant. All data are shown as the
mean  standard error of measurement (SEM). Significance was
accepted at p < 0.05. Unless indicated otherwise for clarity, signif-
icant comparisons are represented as follows: *p< 0.05, **p< 0.01,
***p < 0.001, and ****p < 0.0001.
3. RESULTS
3.1. Selective disruption of KSR2 in the brain causes obesity
Nes-Cre mice were crossed to KSR2fl/fl mice to generate Nes-
CreKSR2fl/fl mice deleted in exon 3 of the KSR2 gene (Figure 1,
schematic of strategy in panel A and PCR analysis indicating deletion of
exon 3 in panel B). Western blotting revealed strong expression of
KSR2 in brains from WT, Nes-Cre, and KSR2fl/fl mice but no detectable
KSR2 in brains from Nes-CreKSR2fl/fl mice (Figure 1C). qPCR from
selected tissues showed that KSR2 mRNA was undetected in brains
from Nes-CreKSR2fl/fl mice; however, KSR2 mRNA was detectable and
not significantly changed, relative to control mice, in the pituitary, liver,
white adipose tissue (WAT), quadriceps muscle (Quad), and kidney of
Nes-CreKSR2fl/fl mice (Figure 1D). As we observed previously [5],
KSR2 was undetectable by qPCR in brown adipose tissue from mice of
any genotype (not shown). The GTex portal indicates that KSR2
expression is high in the human pituitary gland [1A]. Of importance, our
data confirm similar high-level expression of KSR2 mRNA in the pi-
tuitary of C57BL/6 mice (Figure 1D), and the nestin promoter is clearly
not active in the gland, as KSR2 expression was not different between
Nes-CreKSR2fl/fl mice and WT controls.
Nes-CreKSR2fl/fl mice showed a significant increase in body mass
relative to control mice beginning at 12 and 16 weeks of age,
respectively (Figure 2A). Despite the absence of detectable KSR2 in
brain, the rate and degree of growth in Nes-CreKSR2fl/fl mice were
notably less than those observed in KSR2/ mice (Figure 2A,B;
compare right-hand panels to left). To determine the extent to which
KSR2 expression in brain contributes to adiposity, lean mass and fat
mass were measured in Nes-CreKSR2fl/fl mice from 5 to 20 weeks of
age (Figure 3). Strikingly, lean mass of KSR2/ mice was elevated
relative to WT mice while Nes-CreKSR2fl/fl mice exhibited no significant
difference in lean mass in comparison to controls (Figure 3B).
Relative to Nes-Cre and KSR2fl/fl mice, male Nes-CreKSR2fl/fl mice
showed a significant increase in total fat mass by 8 weeks of age. In
female Nes-CreKSR2fl/fl mice, total adipose mass was not significantly
different from controls until 16 weeks of age. Fat mass accumulated in
female Nes-CreKSR2fl/fl mice at about half the rate of male Nes-
CreKSR2fl/fl mice (Figure 3A), which likely explains why total body
mass in female Nes-CreKSR2fl/fl mice was not significantly different
from control mice until that time (Figure 2A). Female KSR2/ mice
were markedly more obese than female Nes-CreKSR2fl/fl mice, which
still had twice the body fat of control mice at 20 weeks of age. We
recently observed that whole-body disruption of KSR2 results in a
significant decrease in nose-to-anus length, accompanied by a
decrease in bone mineral content and density. The skeletal deficit
appears to result from a cell non-autonomous decline of hepatic IGF-1
expression and can be rescued by infection of KSR2/ neonates with
an adenovirus encoding an IGF-1 transgene [15]. This decrease in
body length is recapitulated in the Nes-CreKSR2fl/fl mice. At five
months of age, Nes-CreKSR2fl/fl males and females are significantly
shorter than control KSR2fl/fl mice [for males: 9.1  0.05 cm for Nes-
CreKSR2fl/fl (n ¼ 10) vs 9.6  0.07 cm for KSR2fl/fl (n ¼ 11); for
females: p < 0.0001; 8.8  0.07 cm for Nes-CreKSR2fl/fl (n ¼ 9) vs
9.2  0.08 cm for KSR2fl/fl (n ¼ 11), p < 0.001].
As with KSR2/ mice [5], the adiposity of Nes-CreKSR2fl/fl mice re-
sults from a general increase in the mass of all adipose depots,
including brown adipose tissue (Figure 4A). Similar to the enlarged
adipocytes observed in KSR2/ mice [5], disruption of KSR2 selec-
tively in the brain also increases adipocyte size (Figure 4B). In contrast,
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KSR2/ mice show a greater degree of hyperphagia than Nes-
CreKSR2fl/fl mice, which likely contributes to their greater adiposity.
Indeed, female Nes-CreKSR2fl/fl mice do not eat significantly more than
control Nes-Cre or KSR2fl/fl mice (Figure 4C).
KSR2/mice are reported to be resistant to leptin after being pair-fed
for 14 days [11]. However, in KSR2/ mice fed ad libitum, leptin
inhibits overnight food consumption though not to the degree observed
in WT mice [5]. We examined the effect of leptin on Nes-CreKSR2fl/fl
mice and KSR2fl/fl controls. In contrast to the global disruption of KSR2
(Figure 4D, lower panel), which diminished the ability of leptin to inhibit
food consumption in mice fed ad libitum, leptin inhibited food intake to
the same degree in Nes-CreKSR2fl/fl mice than it did in control animals.
This was true even when mice were injected successively with mul-
tiple leptin doses (Figure 4D, upper panel). Thus, the selective
disruption of KSR2 in the brain has no effect on leptin responsiveness,
which likely contributes to the more modest obesity observed by
disruption of KSR2 in the brain alone.
3.2. Brain KSR2 is required for normal metabolism of glucose and
lipids
KSR2/ mice show marked defects in glucose metabolism [5,13].
Glucose tolerance tests revealed glucose intolerance in Nes-
CreKSR2fl/fl mice at five months of age (Figure 5A). Fasting insulin
was elevated in male and, to a lesser degree, female, Nes-CreKSR2fl/fl
Figure 2: Disruption of KSR2 in the brain causes obesity. A. Body mass measurements of male (n ¼ 9e12) and female (n ¼ 6e11) mice with the indicated genotypes. Asterisks
above open circles indicate significant differences between Nes-CreKSR2fl/fl and KSR2fl/fl mice. B. Analysis of body composition by dual energy absorptiometry (DEXA) for
representative male and female mice of the indicated genotypes.
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mice (Figure 5B). Insulin levels in male Nes-CreKSR2fl/fl mice were
increased relative to their controls, which is comparable to the effect
seen in KSR2/mice vs. the WT control. Serum free fatty acids (FFA)
were similarly increased in Nes-CreKSR2fl/fl mice relative to control
animals (Figure 5C). FFA levels were comparable to that observed in
KSR2/ mice, despite a relatively lower level of adiposity. Defects in
glucose tolerance, insulin, and FFA were not evident until after the
onset of obesity. At 5e7 weeks of age, lean KSR2/ and Nes-
Figure 3: eBrain-specific disruption of KSR2 has a less pronounced effect on lean mass and fat mass than whole-body KSR2 knockout. Measurements of lean mass (A) and fat
mass (B) for male (n ¼ 9e12) and female (n ¼ 6e11) mice of the indicated genotypes. Asterisks above open circles show significant differences between Nes-CreKSR2fl/fl and
KSR2fl/fl mice.
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Figure 5: Glucose tolerance, fasting serum insulin, and free fatty acid levels in Nes-CreKSR2fl/fl and KSR2/ mice. A: Glucose tolerance test in five-month-old Nes-CreKSR2fl/fl
and KSR2/ male (n ¼ 7e14) and female (n ¼ 9e14) mice. Fasting insulin (B) and serum free fatty acid (C) levels in Nes-CreKSR2fl/fl and KSR2/ male (n ¼ 4e10) and female
(n ¼ 6e8) mice.
Figure 4: Adiposity, food consumption, and leptin sensitivity in mice with brain-specific disruption of KSR2. A: Wet weights of subcutaneous (SQ), inguinal (ING), retroperitoneal
(RP), and brown (BAT) adipose tissue in male (n ¼ 4e7) and female (n ¼ 5e8) mice of the indicated genotypes. B: Hematoxylin and eosin staining of SQ adipose tissue from mice
of the indicated genotypes. C: Average daily food intake in males (left, n ¼ 5e12) and females (right, n ¼ 8e11). D: Chronic leptin treatment of 6e7 month-old male (n ¼ 4e6)
mice of the indicated genotypes.
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CreKSR2fl/fl mice showed no difference in their ability to handle a
glucose load and no significant elevation in fasting insulin or FFA
(Figure S1). These data suggest that defects in glucose homeostasis
may be secondary to the obesity caused by disruption of KSR2 in the
brain.
KSR2/ mice show a marked decrease in response to AICAR treat-
ment, a measure of whole-body response to the activation of AMPK
after injected AICAR is metabolized into the allosteric activator, ZMP
[5,13]. Selective disruption of KSR2 in the brains of Nes-CreKSR2fl/fl
mice did not affect AICAR tolerance before or after the onset of obesity
(Figure. S2A, Figure 6), suggesting that KSR2 functions in a tissue other
than the brain to alter AMPK effects on whole-body glucose metabolism.
3.3. KSR2 in the brain affects thermogenesis
In the DBA1/LacJ background, global disruption of KSR2 reduces rectal
and core body temperatures during both quiescent (day) and active
(night) periods relative to WT mice. This difference is evident even at
thermoneutrality [5]. In contrast, in the C57BL6/J background, no dif-
ference in body temperature is evident during the active period in
KSR2/ mice compared to WT mice or between mice with brain-
specific disruption of KSR2 and their controls (Figure 7A). However,
the typical drop in temperature that occurs during the quiescent period
(2 pm) is exacerbated by the disruption of KSR2 throughout the body, or
selectively in the brain (Figure 7A). This reduced thermogenic capacity is
apparent at 5e7 weeks of age and may be a key contributor to the
obesity and insulin-resistant phenotype seen in mature animals. While
UCP1 mRNA is significantly decreased in brown adipose tissue (BAT) of
KSR2/ mice, it only trends lower, but not significantly so, in Nes-
CreKSR2fl/fl mice (Figure 7B). However, the marked intolerance of the
mice to acute cold exposure at 4 C when fasted (Figure 7C) and the
overt accumulation of lipid in the BAT of Nes-CreKSR2fl/fl and KSR2/
mice (Figure 7D) indicate a distinct defect in energy metabolism resulting
from the loss of KSR2 in brain that compromises thermogenesis.
4. DISCUSSION
Here we show that brain-specific disruption of the molecular scaffold
KSR2 phenocopies the obesity and glucose intolerance of whole-body
KSR2 knockout, although the degree of adiposity and glucose intol-
erance and the increased circulating insulin in fasting Nes-CreKSR2fl/fl
mice is less than that observed with whole-body knockout of KSR2.
KSR2/ and Nes-CreKSR2fl/fl brain-specific knockout mice show
comparable defects in body temperature maintenance and cold
tolerance. However, there are also deficits in the KSR2/ mice that
are not present when KSR2 is selectively disrupted in the brain. Though
KSR2/ mice are insensitive to AICAR treatment, Nes-CreKSR2fl/fl
mice do not differ from their controls in sensitivity to AICAR (Figure 6).
Further, leptin demonstrates its full acute anorexigenic effect in Nes-
CreKSR2fl/fl mice, while its actions are blunted in KSR2/ mice
(Figure 4D). Thus, although a large component of the effects of KSR2 to
regulate energy intake and expenditure leading to obesity operates
through KSR2-modulated signals from the brain, at least one other cell
non-autonomous mechanism must contribute significantly to KSR2-
dependent energy balance.
The precise brain region(s) in which KSR2 functions have yet to be
identified, but circumstantial evidence supports the notion that KSR2
expression within discrete nuclei of the hypothalamus is critical for
normal energy balance. Mice lacking KSR2 in the brain and whole body
share notable similarities to, but also striking differences from, mice
lacking the Mc4r receptor. Similar to the Nes-CreKSR2fl/fl and KSR2/
mice, mice mutant or nullizygous for expression of Mc4r become
obese around 5e7 weeks of age and exhibit hyperphagia [18,19]. Like
KSR2 [5,12], Mc4r also regulates energy balance, at least in part by
promoting energy expenditure [18]. However, the hyperphagic, obese
and glucose-intolerant phenotype of KSR2/ mice on the C57BL/6
background is markedly more severe than that of the Mc4r/ mice
[11]. Treatment with the Mc4r agonist MTII attenuated the hyperphagia
Figure 6: AICAR tolerance is impaired in KSR2/ mice but not in Nes-CreKSR2fl/fl, mice. AICAR tolerance was tested in five-month-old male (n ¼ 7e14) and female (n ¼ 9e14)
Nes-CreKSR2fl/fl and KSR2/ mice and analyzed relative to controls.
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Figure 7: Nes-CreKSR2fl/fl and KSR2/ male mice have decreased rectal temperature and cold intolerance. A: Rectal temperatures from 5-month-old male (left, n ¼ 5e11) and
female (right, n ¼ 8e12) mice. B: qPCR of UCP1 mRNA from BAT. C: Cold tolerance in 6-month-old KSR2/ and Nes-CreKSR2fl/fl fasted mice. D: Hematoxylin and eosin staining
of BAT from mice of the indicated genotypes.
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of KSR2/ mice [11], suggesting that KSR2 functions upstream of
Mc4r. Opposing effects on body length also distinguish the physiology
of KSR2 from Mc4r. Mc4r disruption causes an increase in nose to
anus length [18,19]. In contrast, mice lacking KSR2 have a significantly
decreased nose to anus length that can be rescued by correcting the
neonatal defect in hepatic IGF-1 expression with adenovirus-mediated
introduction of a KSR2 transgene [15]. These data indicate that KSR2
does not mediate the actions of Mc4r on energy balance.
a-MSH stimulation of Mc4r within the paraventricular nucleus (PVN) of
the hypothalamus suppresses food intake and increases energy
expenditure [20]. In contrast, the Mc4r inverse agonist, Agouti gene-
related peptide (AgRP) is produced by an opposing set of neurons in
the arcuate, which are activated during caloric insufficiency. The
orexigenic neuropeptide Y (NPY) is co-expressed with AgRP, and, when
activated, these anabolic neurons promote feeding behavior, energy
storage, and weight gain. Leptin impinges upon the melanocortin
system, activating POMC neurons and inhibiting NPY/AgRP neurons
[3]. The possibility that KSR2 is involved in Mc4r signaling is supported
by reports that AgRP, NPY and POMC are significantly reduced in 6-
week-old KSR2/ mice [11]. However, by 8e9 months of age, no
differences in these neuropeptides were observed between WT and
KSR2/ mice, on the DBA1Lac/J background [5]. These seemingly
conflicting data may reveal a role for KSR2 in regulating the rate at
which neuronal connections are formed in the brain, which can have a
potent impact on the development of neural control over energy bal-
ance [21].
At least some connections between hypothalamic nuclei controlling
energy balance appear to form developmentally in response to a
transient, postnatal surge in leptin [22]. KSR2 may play a critical role
in their formation affecting the ability of these nuclei to sense and
respond to nutrient status. KSR2/ mice on the C57BL/6 back-
ground [11e13], but not the DBA1Lac/J background [5], develop
hyperphagic behavior leading to obesity. These data reveal the
presence of strain-specific genetic modifiers that affect the expres-
sion of KSR2-dependent phenotype. Food restriction of C57BL/6
KSR2/ mice after weaning prevents them from becoming obese
and alleviates defects in lipid and glucose metabolism [13]. However,
this effect is temporary; once KSR2/ mice resume ad libidum
feeding, hyperphagia and obesity return. Insensitivity to the anorex-
igenic adipokine leptin may account for the hyperphagia. Since Nes-
CreKSR2fl/fl do not display insensitivity to leptin shown by KSR2/
mice, what is the molecular basis for this insensitivity? One possibility
is that poor response to leptin observed in KSR2/ mice reflects
hypothalamic inflammation. Hypothalamic inflammation can occur in
response to a high-fat diet (HFD)-induced downregulation of PGC1a-
mediated expression of ERRa [23]. Leptin insensitivity is evident in
both male and female KSR2/ mice (Figure 4D and unpublished
data). However, HFD-induced effects are evident only in male C57BL/
6 mice [23]. Thus, if KSR2 expression regulates hypothalamic
inflammation, it likely does so via a mechanism that is not gender-
specific.
In our initial report of an effect of KSR2 on energy balance [5], we
proposed that the reduced responsiveness to AICAR observed in
KSR2/ mice reflected an increase in triglyceride storage and a
deficit in mitochondrial import and oxidation of fatty acids resulting
from the diminished ability of AMPK to inhibit acetyl CoA carboxylase
and impede malonyl CoA synthesis [5]. In vitro studies with KSR2 and
the closely related protein KSR1 show that these molecular scaffolds
can interact directly with AMPK and promote phosphorylation of AMPK
substrates [5,7,24]. Furthermore, while global KSR2 disruption
markedly reduces AMPK activation in white adipose tissue, little, if any,
KSR2 is expressed in fat (Figure 1D), and no KSR2 is detected in BAT
[5]. These data strongly suggest that the KSR2-dependent effects on
AMPK-regulated fatty acid metabolism can be both cell autonomous
and cell non-autonomous. These observations in combination with the
effect of KSR2 on body temperature suggest that BAT may be a key
target of KSR2 action. Cell non-autonomous regulation of AMPK and its
substrate acetyl CoA carboxylase (ACC) in BAT by KSR2 may be
essential for normal fatty acid metabolism in BAT. KSR2 disruption may
affect body weight by interrupting AMPK-mediated inhibition of ACC
activity in BAT, impairing fat metabolism and heat generation while
promoting fatty acid storage as triglycerides.
Cell autonomous effects of KSR2 on AMPK function may occur in the
brain and contribute to altered energy balance. Disruption of KSR2
enhances the phosphorylation and activation of mTOR [11], and sus-
tained mTOR activation in the hypothalamus promotes obesity [25].
Phosphorylation of TSC2 and Raptor by AMPK inhibits mTOR anabolic
activity [26e30]. Thus, it is possible that KSR2 disruption promotes
mTOR-mediated effects on energy balance via loss of AMPK-mediated
phosphorylation of key mTOR regulators. However, it should be noted
that hypothalamic mTOR-mediated obesity was obtained by disruption
of TSC1 and was accompanied by hyperphagia [25], which is only
evident in Nes-male CreKSR2fl/fl mice (Figure 4C). Thus, extensive
analysis is still required to understand the role(s) of these effectors in
the action of brain KSR2.
The normal response to AICAR observed in Nes-CreKSR2fl/fl mice in-
dicates that this cell non-autonomous effect of KSR2 on AMPK is not
mediated by the brain. Based on tissue distribution (Figure 1D and ref.
1A), the pituitary is a strong candidate for mediating KSR2-dependent
control of AMPK. The maintenance of robust KSR2 expression in the
pituitary of Nes-CreKSR2fl/fl mice may explain why their obesity is not
as severe as that observed in KSR2/ mice. If correct, this may
indicate that KSR2 regulates the timing or extent of secretion of
specific hormones from the anterior pituitary that affect the daily
control of tissue responsiveness to AMPK-dependent energy sensing
or influence the acquisition, during development, of normal AMPK
responsiveness to energy stress. In this regard, thyroid hormones are
well-established regulators of energy expenditure and thermogenesis
[31], and a reduction in TSH secretion might account for some of the
effects of KSR2 knockout. However, thyroxine levels in KSR2/ mice
are not significantly different from controls [5]. KSR2/ mice are
reduced fertility (unpublished data). Initial analysis of reproductive
capability indicates that male and female Nes-CreKSR2fl/fl mice have
reduced fertility relative to controls, suggesting the possibility that
gonadotropin secretion or responsiveness may require KSR2. Given the
fact that obese humans with KSR2 mutations phenocopy the disruption
of KSR2 in mice [12], future work detailing the mechanism of KSR2
function in the brain and identifying other KSR2-expressing tissues that
control energy balance is likely to reveal novel mechanisms controlling
peripheral metabolism.
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